Pay in 4 interest-free payments of $7.25 Learn more
Ships within 48 hours · Estimated delivery Sep 8 - Sep 13
IGF-1 LR3 (1 mg) is a synthetic recombinant analog of insulin-like growth factor-1 (IGF-1), categorized under growth factor and muscle biology research peptides, and supplied exclusively for laboratory research use
The participants' average duration of use was 8.3 months, with an average weight loss of 11.3 kg
tirzepatide trials extended to 72 weeks Population size: Phase 2 trials have smaller participant numbers Protocols: Different study designs and endpoints Reported Adverse Events The 2025 meta-analysis reported on adverse event frequency from the published trial data: The meta-analysis noted that adverse events were more frequent with retatrutide (RR 4.10) compared to tirzepatide (RR 2.78)
This MDL is the Federal consolidated lawsuit against the manufacturers of GLP-1 drugs, like Zepbound
Neurological Symptoms: Numbness, tingling, or weakness not related to the injection site
